Funding opportunities
2,259 live opportunities from Grants.gov, NIH, NSF, and more.
Biomedical & Health× remove
- Cross-Tissue Multi-Omic Predictors of Allergic Disease Development and Progression in Early LifeNational Institute of Allergy and Infectious DiseasesPA-25-301 closes 5/31/2031up to $1,625,664activenih
- Delineating the role of TREM2 in chronic pancreatitisNational Cancer InstitutePA-25-301 closes 5/31/2031up to $374,006activenih
- Deciphering the Gating Mechanism of Intraflagellar Transport in Trypanosoma bruceiNational Institute of Allergy and Infectious DiseasesPA-25-301 closes 5/31/2031up to $718,028activenih
- Identification and inhibition of the novel downstream effectors of mutant Ras for mutant Ras-driven cancer targetingNational Cancer InstitutePA-25-301 closes 5/31/2031up to $693,403activenih
- Dietary and Microbial Strategies to Suppress Antibiotic-Induced AMR in the Gut MicrobiomeNational Institute of Allergy and Infectious DiseasesPA-25-301 closes 5/31/2031up to $847,217activenih
- Prospective Detection and Monitoring of NF1 peripheral nerve sheath tumors using cell-free DNANational Cancer InstitutePA-25-301 closes 5/31/2031up to $688,661activenih
- A Randomized Control Trial of a Scalable Parenting Program to support Candidate Brain Pathways, Autonomic Regulation, and Socio-Emotional Development in Preterm InfantsEunice Kennedy Shriver National Institute of Child Health and Human DevelopmentPA-25-305 closes 5/31/2031up to $597,736activenih
- Enhancing Orthographic Communication and Literacy Outcomes for AAC Users: Investigating Effective Instructional StrategiesNational Institute on Deafness and Other Communication DisordersPA-25-303 closes 5/31/2031up to $766,451activenih
- PbViVac: readying an effective first-generation vaccine for P. vivax malariaNational Institute of Allergy and Infectious DiseasesPA-25-301 closes 5/31/2031up to $824,264activenih
- Computational prediction of anti-cancer drug metabolizing enzymes in the human microbiomeNational Cancer InstitutePA-25-301 closes 5/31/2031up to $747,790activenih
- Mentoring Patient-Oriented Research in the Evaluation of Novel Diagnostics for People With Advanced HIV DiseaseNational Institute of Allergy and Infectious DiseasesPA-24-188 closes 5/31/2031up to $220,485activenih
- Understanding inflammatory cell death as a driver of VEXAS pathogenesisNational Cancer InstitutePA-24-182 closes 5/31/2031up to $294,451activenih
- Neutralizing and FcR-mediating antibody specificities and function in control of HHV-8 infectionNational Institute of Allergy and Infectious DiseasesPAR-23-073 closes 5/31/2031up to $211,008activenih
- Development of Genomic Risk Prediction Models for T-cell MalignanciesNational Cancer InstitutePA-24-182 closes 5/31/2031up to $276,545activenih
- Role of CXCR6+ T-cells in ICI myocarditisNational Heart Lung and Blood InstitutePA-24-182 closes 5/31/2031up to $163,188activenih
- Facilitating Accelerated Science and Translation for TB Regimen Development (FAST-TB)National Institute of Allergy and Infectious DiseasesPAR-23-065 closes 5/31/2031up to $3,499,366activenih
- Targeting PTPN22 for Novel Cancer Immunotherapeutic AgentsNational Cancer InstitutePA-25-301 closes 5/31/2031up to $593,249activenih
- Identifying Biobehavioral Predictors and Targeting Mechanisms of Intervention in Adolescent Posttraumatic Stress DisorderNational Institute of Mental HealthPA-24-184 closes 5/31/2031up to $206,547activenih
- Quantitative Multiparametric PSMA PET MR to Optimize Treatment Planning for Partial Gland Ablation of Prostate CancerNational Cancer InstitutePAR-25-081 closes 5/31/2031up to $709,677activenih
- PARSEC: Plasmodium falciparum Adaptive Response to Sickle trait ErythrocytesNational Institute of Allergy and Infectious DiseasesPA-25-301 closes 5/31/2031up to $788,379activenih
- Signal relay during directed cell migration and inflammation in skinNational Institute of Allergy and Infectious DiseasesPA-25-301 closes 5/31/2031up to $690,883activenih
- Protein O' Mannosylation as a therapeutic vulnerability in KIAA1549-BRAF-driven pediatric low-grade gliomaNational Cancer InstitutePA-25-301 closes 5/31/2031up to $721,653activenih
- Optimization of a novel and effective antiviral agent targeting Zika NS4BNational Institute of Allergy and Infectious DiseasesPA-25-301 closes 5/31/2031up to $139,920activenih
- Atypical Sphingolipids in healthy and diseased liverNational Cancer InstitutePA-25-301 closes 5/31/2031up to $634,062activenih
- Coordinating Central Tolerance: Defining Distinct Roles for Nr4a1 and Nr4a3 in Thymocyte SelectionNational Institute of Allergy and Infectious DiseasesPA-24-182 closes 5/31/2031up to $201,744activenih